Further complicating the retrofitting of COX-2 positivity within established breast cancer subtypes is the fact that COX-2 expression and function may originate from non-epithelial cellular components of the microenvironment such as the immune response, or the tissue response to injury. Here, PTGS2 is linked to breast cancer.